Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Acceleron Pharma (XLRN) Misses Q4 EPS by 36c, Revenues Miss
February 25, 2021 4:30 PM ESTAcceleron Pharma (NASDAQ: XLRN) reported Q4 EPS of ($0.95), $0.36 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $25.87 million versus the consensus estimate of $32.31 million.
2020 was a very productive year for Acceleron as we generated important results in our lead pulmonary program to advance sotatercept into a... More
